Adjuvant antibody therapy with trastuzumab in early breast cancer

被引：0
|
作者：
Untch, Michael
Scharl, Anton
Jackisch, Christian
Thomssen, Christoph
Nitz, Ulrike
von Minckwitz, Gunter
Harbeck, Nadia
机构：
[1] Univ Charite, Akad LK, Helios Klinikum Berlin Buch, Frauenklin,Interdisziplinaires Brustzentrum, D-13125 Berlin, Germany
[2] Frauenklin Amberg, Amberg, Germany
[3] Frauenklin Offenbach, Offenbach, Germany
[4] Univ Halle Wittenberg, Frauenklin, D-4010 Halle, Germany
[5] Univ Dusseldorf, Frauenklin, D-4000 Dusseldorf, Germany
[6] GBG Forsch GmbH, Neu Isenburg, Germany
[7] Tech Univ Munich, Frauenklin, D-8000 Munich, Germany
来源：
BREAST CARE | 2006年 / 1卷 / 04期
关键词：
HER2/neu; monoclonal antibody; breast cancer; trastuzumab; adjuvant therapy;
D O I：
10.1159/000094891
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy with the monoclonal antibody trastuzumab is a well established cornerstone of an individualized treatment strategy for women with HER2/neu-over-expressing breast cancer. Based on the reported data of clinical studies comprising more than 14,000 women, trastuzumab was approved throughout the European Union in May 2006 for adjuvant therapy in patients with early-stage HER2/neu-overexpressing breast cancer.
引用
收藏
页码：252 / 255
页数：4
相关论文
共 50 条
  • [31] Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab
    Seal, M. D.
    Speers, C. H.
    O'Reilly, S.
    Gelmon, K. A.
    Ellard, S. L.
    Chia, S. K.
    [J]. CURRENT ONCOLOGY, 2012, 19 (04) : 197 - 201
  • [32] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [33] Efficacy of short-course adjuvant trastuzumab in early stage breast cancer
    Saifo, M.
    Nikoula, M.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [34] Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer
    Mikiya Ishihara
    Hirofumi Mukai
    Shunji Nagai
    Toru Mukohara
    [J]. International Journal of Clinical Oncology, 2009, 14 : 431 - 435
  • [35] TRASTUZUMAB THERAPY FOR EARLY BREAST CANCER IN THE REAL-WORLD
    Marla, S.
    Cooke, T. G.
    Roxburgh, P.
    Burton, P.
    Mallon, E.
    Stallard, S.
    Canney, P.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 85 - 86
  • [36] Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
    Chen, Jersey
    Long, Jessica B.
    Hurria, Arti
    Owusu, Cynthia
    Steingart, Richard M.
    Gross, Cary P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (24) : 2504 - 2512
  • [37] Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: A case report
    Ishizuna K.
    Ninomiya J.
    Ogawa T.
    Tsuji E.
    [J]. Journal of Medical Case Reports, 8 (1)
  • [38] Trastuzumab for early breast cancer
    Smith, IE
    [J]. LANCET, 2006, 367 (9505): : 107 - 107
  • [39] Trastuzumab in early breast cancer
    Ismaili, Nabil
    Elmajjaoui, Sanaa
    Tahri, Ali
    Benjaafar, Noureddine
    Errihani, Hassan
    Belbaraka, Rhizlane
    [J]. PRESSE MEDICALE, 2013, 42 (7-8): : 1069 - 1080
  • [40] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
12345